Linagliptin Krka (Linagliptin)

• Linagliptin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion.
• Type 2 diabetes mellitus: improves glycaemic control by enhancing glucose‑dependent insulin secretion and reducing hepatic glucose production.

• Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which degrades the incretin hormones GLP‑1 and GIP. By preventing this degradation, linagliptin increases circulating incretin levels, leading to glucose‑dependent stimulation of insulin release, suppression of glucagon secretion, and overall improvement of post‑prandial and fasting blood glucose concentrations.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Nasopharyngitis: mild upper‑respiratory tract infection.
• Headache: transient mild to moderate pain.
• Dizziness: occasional light‑headedness.
• Gastrointestinal upset: nausea, abdominal discomfort.
• Upper respiratory infection: cough, sore throat.
• Back pain: musculoskeletal discomfort.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain requiring medical attention.
• Severe allergic reactions: rash, angioedema, anaphylaxis.
• Hepatic injury: elevated liver enzymes or jaundice.
• Hypoglycaemia (when combined with insulin or sulfonylureas): dizziness, sweating, confusion.
• Bullous pemphigoid: blistering skin disorder.
• Stevens‑Johnson syndrome: severe mucocutaneous reaction.

• When prescribing Linagliptin, clinicians should consider several safety aspects.
• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic impairment: use with caution in patients with liver disease.
• Cardiovascular disease: observe for any worsening of cardiac status.
• Elderly patients: start at the recommended dose and monitor for adverse effects.
• Pregnancy and lactation: safety not established; avoid unless clearly needed.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure.
• Insulin or sulfonylureas: heightened risk of hypoglycaemia.
• Rifampin: may lower linagliptin plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Diuretics: watch for electrolyte disturbances.

• ACE inhibitors: monitor blood pressure for additive hypotensive effect.
• Warfarin: assess INR regularly for potential interaction.